|
Real-time Estimate
Cboe BZX
09:32:13 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 22.50 USD | -1.12% |
|
-4.21% | - |
| 09-02 | MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says | MT |
| 09-02 | UBS Raises Price Target on MiniMed to $28 From $25, Keeps Buy Rating | MT |
| Market Cap | 6.4B 5.51B 5.19B 4.73B 8.85B 609B 8.88B 61.49B 23.77B 310B 24.05B 23.52B 983B | P/E 2027 * |
35.6x | P/E 2028 * | 30.6x |
|---|---|---|---|---|---|
| Enterprise Value | 6.11B 5.25B 4.95B 4.51B 8.43B 581B 8.47B 58.64B 22.66B 296B 22.93B 22.43B 938B | EV / Sales 2027 * |
1.78x | EV / Sales 2028 * | 1.56x |
| Free-Float |
10.08% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MMED | Delayed | |
CBOE
| MMED | Real-time | |
|
Tradegate
| B8S | Real-time | |
|
Deutsche Boerse AG
| B8S | Delayed | |
|
Boerse Muenchen
| B8S | Real-time | |
|
Börse Stuttgart
| B8S | Delayed |
Last Transcript : MiniMed Group, Inc.
| 1 day | -0.66% | ||
| 1 week | -4.21% | ||
| Current month | +12.34% | ||
| 1 month | +16.12% | ||
| 3 months | +50.53% | ||
| 6 months | +26.44% |
| 1 week | 22.51 |  | 23.9 |
| 1 month | 18.85 | | 24.43 |
| Current year | 10.65 | | 24.43 |
| 1 year | 10.65 | | 24.43 |
| 3 years | 10.65 | | 24.43 |
| 5 years | 10.65 | | 24.43 |
| 10 years | 10.65 | | 24.43 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/31/26 | Tax | Chief Executive Officer | -31,350 | 0.0112% | ||
| 7/31/26 | Tax | Chief Technology Officer | -8,012 | 0.0029% | ||
| 7/31/26 | Tax | General Counsel | -1,762 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.36% | -4.21% | - | - | 6.4B | |
| -0.24% | -1.00% | +11.31% | +9.08% | 12.59B | |
| -0.67% | -2.70% | +12.77% | +25.48% | 6.75B | |
| -0.80% | -10.34% | +20.10% | +7.58% | 5.63B | |
| -0.16% | -2.44% | -22.44% | +40.54% | 4.96B | |
| +0.23% | -0.96% | -36.47% | -21.47% | 3.82B | |
| -3.20% | -12.34% | +23.46% | -21.97% | 1.82B | |
| +2.01% | +3.54% | -3.61% | +139.30% | 1.76B | |
| -3.05% | -1.94% | +42.19% | -19.41% | 1.64B | |
| -0.15% | +0.10% | -7.76% | +33.73% | 1.39B | |
| Average | -0.61% | -2.45% | +4.40% | +21.43% | 4.68B | |
| Weighted average by Cap. | -0.51% | -2.85% | +4.61% | +16.58% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 3.44B 2.96B 2.78B 2.54B 4.75B 327B 4.77B 33B 12.76B 167B 12.91B 12.63B 528B | 3.72B 3.2B 3.01B 2.75B 5.14B 354B 5.16B 35.72B 13.81B 180B 13.97B 13.67B 571B |
| Net income | 181M 156M 146M 133M 250M 17.2B 251M 1.74B 671M 8.76B 679M 664M 27.77B | 239M 206M 194M 176M 330M 22.74B 331M 2.29B 887M 11.59B 897M 878M 36.7B |
| Net Debt | -297M -256M -241M -219M -410M -28.27B -412M -2.85B -1.1B -14.4B -1.12B -1.09B -45.62B | -600M -516M -486M -443M -829M -57.11B -832M -5.76B -2.23B -29.1B -2.25B -2.2B -92.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-09 | US$22.76 | -2.40% | 1,587,725 |
| 26-09-08 | US$23.32 | +0.15% | 1,052,149 |
| 26-09-04 | US$23.29 | -2.33% | 1,719,503 |
| 26-09-03 | US$23.84 | +0.34% | 4,268,141 |
| 26-09-02 | US$23.76 | +5.98% | 4,491,890 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MMED Stock
Select your edition
All financial news and data tailored to specific country editions
